The company
Summit Therapeutics Inc.
SMMT · Nasdaq
SMMT stood above a rising 150-day average in 4 of the last 52 weekly readings, and has been out of that trend for the last 1 week. It is 10.5% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 1
- Industry in uptrend
- 15% -17 in 4 wk
- Insider buys, 12 months
- $218.2M
- Insider sales, 12 months
- $0
- Officials’ trades on record
- 0
- Institutions holding
- 228 (+16)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 4 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Robert W. DugganCo-Chief Executive Officer | bought | 3,810,000at $13.12 | 12 Jun 2026filed 12 Jun 2026 |
| Mahkam ZanganehCo-Chief Executive Officer | bought | 3,810,000at $13.12 | 12 Jun 2026filed 12 Jun 2026 |
| Robert W. DugganCo-Chief Executive Officer | bought | 100,000at $14.60 | 4 Jun 2026filed 4 Jun 2026 |
| Mahkam ZanganehCo-Chief Executive Officer | bought | 100,000at $14.60 | 4 Jun 2026filed 4 Jun 2026 |
| Manmeet Singh SoniCOO and CFO | bought | 25,000at $14.46 | 4 Jun 2026filed 4 Jun 2026 |
| Manmeet Singh SoniCOO and CFO | bought | 25,000at $14.43 | 4 Jun 2026filed 4 Jun 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| BAKER BROS. ADVISORS LPreduced · filed 14 Aug 2026 | 32,786,348$477.7M | -3,604,715−9.9% |
| FMR LLCreduced · filed 13 Aug 2026 | 10,043,947$146.3M | -809,252−7.5% |
| STATE STREET CORPadded · filed 7 Aug 2026 | 9,536,796$139.0M | +2,508,636+35.7% |
| BlackRock, Inc.reduced · filed 7 Aug 2026 | 9,529,041$138.8M | -124,717−1.3% |
| VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026 | 5,734,484$83.6M | +22,682+0.4% |
| UBS Group AGadded · filed 13 Aug 2026 | 5,233,798$76.3M | +1,553,483+42.2% |
| VANGUARD PORTFOLIO MANAGEMENT LLCreduced · filed 13 Aug 2026 | 5,042,190$73.5M | -191,062−3.7% |
| GOLDMAN SACHS GROUP INCadded · filed 14 Aug 2026 | 4,513,399$65.8M | +4,202,671+1352.5% |
| Point72 Asset Management, L.P.added · filed 14 Aug 2026 | 3,697,803$53.9M | +2,913,617+371.5% |
| GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026 | 3,427,263$50.0M | +111,409+3.4% |
News
No headline names it lately.
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.